Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer

Journal of Clinical Oncology

Volumn 21, Issue 6, 2003, Pages 976-983

  Henderson, I Craig ^a   Berry, Donald A ^b   Demetri, George D ^b   Cirrincione, Constance T ^b   Goldstein, Lori J ^b   Martino, Silvana ^b   Ingle, James N ^b   Cooper, M Robert ^b   Hayes, Daniel F ^b   Tkaczuk, Katherine H ^b   Fleming, Gini ^b   Holland, James F ^b   Duggan, David B ^b   Carpenter, John T ^b   Frei III, Emil ^b   Schilsky, Richard L ^b   Wood, William C ^b   Muss, Hyman B ^b   Norton, Larry ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PACLITAXEL; TAMOXIFEN; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC;

ADJUVANT THERAPY; ARTICLE; BREAST CANCER; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE SEQUENCE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; ADULT; AGED; BREAST TUMOR; DISEASE FREE SURVIVAL; LYMPH NODE METASTASIS; MIDDLE AGED; PATHOLOGY; PROPORTIONAL HAZARDS MODEL;

ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; FEMALE; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; PACLITAXEL; PROPORTIONAL HAZARDS MODELS; TREATMENT OUTCOME;

EID: 0037445132     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.02.063     Document Type: Article

References (24)

1. Early Breast Cancer Trialists Collaborative Group: Polychemotherapy for early breast cancer: An overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 352:930-934, 1998
2. Fisher B, Brown AM, Dimitrov NV, et al: Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: Results from National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol 8:1483-1496, 1990
3. Holmes FA, Walters RS, Theriault RL, et al: Phase II trial of Taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 83:1797-1805, 1991
4. Seidman AD, Norton L, Reichman BS, et al: Preliminary experience with paclitaxel (Taxol) plus recombinant human granulocyte colony-stimulating factor in the treatment of breast cancer. Semin Oncol 20:40-45, 1993
5. Sledge GW, Neuberg D, Ingle J, et al: Phase III trial of doxorubicin (A) vs. paclitaxel (T) vs. doxorubicin + paclitaxel (A+T) as first-line therapy for metastatic breast cancer (MBC): An Intergroup trial. Proc Am Soc Clin Oncol 16:1a, 1997 (abstr 2)
6. Paridaens R, Biganzoli L, Bruning P, et al: Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: A European Organization for Research and Treatment of Cancer randomized study with cross-over. J Clin Oncol 18:724-733, 2000
7. Wood WC, Budman DR, Korzun AH, et al: Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med 330:1253-1259, 1994
8. Budman DR, Berry DA, Cirrincione CT, et al: Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer: The Cancer and Leukemia Group B. J Natl Cancer Inst 90:1205-1211, 1998
9. Fisher B, Anderson S, Wickerham DL, et al: Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-22. J Clin Oncol 15:1858-1869, 1997
10. Fisher B, Anderson S, DeCillis A, et al: Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: Findings from national surgical adjuvant breast and bowel project B-25. J Clin Oncol 17:3374-3388, 1999
11. Box GEP, Hunter WG, Hunter JS: Statistics for experimenters: An introduction to design, data analysis, and model building. New York, NY, Wiley, 1978
12. DeGroot MH: Probability and Statistics (ed 2). Reading, MA, Addison-Wesley, 1987
13. Coates AS, Gelber RD, Goldhirsch A: Subsets within the chemotherapy overview. International Breast Cancer Study Group. Lancet 352:1783-1784, 1998 (letter)
14. Shapiro CL, Hardenbergh PH, Gelman R, et al: Cardiac effects of adjuvant doxorubicin and radiation therapy in breast cancer patients. J Clin Oncol 16:3493-3501, 1998
15. Fumoleau P, Brémond A, Kerbrat P, et al: Better outcome of premenopausal node-positive (N+) breast cancer patients (pts) treated with 6 cycles vs 3 cycles of adjuvant chemotherapy: Eight year follow-up results of FASG 01. Proc Am Soc Clin Oncol 18:67a, 1999 (abstr 252)
16. Legha SS, Benjamin RS, Mackay B, et al: Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med 96:133-139, 1982
17. Hortobagyi GN, Buzdar AU, Theriault RL, et al: Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma. J Natl Cancer Inst 92:225-233, 2000
18. Rodenhuis S, Richel DJ, van der Wall E, et al: Randomised trial of high-dose chemotherapy and haematopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement. Lancet 352:515-521, 1998
19. Bergh J, Wiklund T, Erikstein B, et al: Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: A randomised trial. Scandinavian Breast Group 9401 study. Lancet 356:1384-1391, 2000
20. Peters W, Rosner G, Vredenburgh J, et al: A prospective, randomized comparison of two doses of combination alkylating agents (AA) as consolidation after CAF in high-risk primary breast cancer involving ten or more axillary lymph nodes (LN): Preliminary results of CALGB 9082/SWOG9114/NCIC MA-13. Proc Am Soc Clin Oncol 18:1a, 1999 (abstr 2)
21. Rodenhuis S, Bontenbal M, Beex LVAM, et al: Randomized phase III study of high-dose chemotherapy with cyclophosphamide, thiotepa and carboplatin in operable breast cancer with 4 or more axillary lymph nodes. Proc Am Soc Clin Oncol 19:74a, 2000 (abstr 286)
22. Muss HB, Thor A, Berry DA, et al: c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 330:1260-1266, 1994
23. Thor AD, Berry DA, Budman DR, et al: erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst 90:1346-1360, 1998
24. Buzdar AU, Singletary SE, Valero V, et al: Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: Preliminary data of a prospective randomized trial. Clin Cancer Res 8:1073-1079, 2002